Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway

Inflammatory bowel disease (IBD) is a chronic gut condition linked to imbalances in the intestinal microbiome. This study focused on Eubacterium rectale (ER), a common beneficial gut bacterium that is often depleted in IBD patients, and asked whether restoring it could reduce intestinal inflammation. Using a mouse model where colitis was chemically induced with dextran sulfate sodium (DSS), the researchers found that giving mice ER significantly improved their symptoms, repaired the gut lining, and lowered levels of inflammatory signaling molecules. The key mechanism discovered was that ER specifically turns up the activity of an enzyme called glutaminase 2 (GLS2), which helps intestinal cells properly process the amino acid glutamine. This improved glutamine metabolism, in turn, puts the brakes on NF-κB — a master switch that drives inflammation when overactivated. When the researchers experimentally removed GLS2, ER lost its ability to fight inflammation, confirming that GLS2 is the critical link. The findings suggest that ER, or therapies designed around it, could represent a targeted strategy for treating IBD by restoring a metabolic pathway rather than simply suppressing the immune system broadly.

• Oral administration of Eubacterium rectale to DSS-treated mice improved clinical colitis symptoms and restored intestinal barrier integrity, as measured by colon length, histological scoring, and tight junction protein expression.
• ER treatment specifically upregulated GLS2 expression in intestinal epithelial cells and normalized DSS-induced disturbances in glutamine metabolism, indicating a bacterium-to-epithelium metabolic signaling axis.
• ER suppressed NF-κB pathway activation and reduced pro-inflammatory cytokine levels; GLS2 knockout experiments confirmed that this anti-inflammatory effect is abolished in the absence of GLS2, establishing GLS2 as an obligate mediator of ER's protective action.

This was a preclinical mouse mechanistic study using a DSS-induced colitis model, a standard and widely accepted approach for modelling acute ulcerative colitis. Mice received Eubacterium rectale by oral gavage, and outcomes included clinical symptom scoring, histopathology, intestinal barrier markers, cytokine profiling, and pathway analysis of GLS2 and NF-κB signaling. Mechanistic causality was probed through GLS2-deficient mouse or cell experiments to confirm the necessity of the GLS2/NF-κB axis. Specific sample sizes, dosing concentrations, and treatment durations are reported in the study but not detailed in the abstract.

As a mouse study using chemically induced colitis, the findings may not directly translate to the heterogeneous, immune-mediated pathology seen in human Crohn's disease or ulcerative colitis, where ER depletion patterns and mucosal environments differ. The study does not address whether ER can survive and colonize the human gut at therapeutically relevant levels, nor does it examine how pre-existing dysbiosis might affect ER engraftment or GLS2 induction. It remains unclear whether the GLS2-activating signal is a specific ER metabolite, a cell-surface component, or a secondary microbiota effect — pinpointing the active molecular effector would be the critical next experiment. Long-term safety, dose-response relationships, and efficacy in chronic or relapsing colitis models are also uncharacterized.

This study extends the broader corpus theme of specific gut bacteria ameliorating DSS-induced colitis through defined molecular pathways, directly paralleling [§118], which examines how a plant-derived polysaccharide reshapes microbiota composition to reduce colitis, but shifts the focus from dietary modulation of community structure to a single commensal species acting through a host metabolic enzyme. It parallels [§144], which surveys how probiotic and commensal strains protect intestinal epithelial integrity and modulate inflammatory signaling, by providing a concrete mechanistic example — the GLS2/NF-κB axis — that gives molecular specificity to the broader probiotic-barrier protection literature. The work also complements [§146], which demonstrates that ulcerative colitis can be alleviated through metabolite-mediated macrophage reprogramming (lithocholic acid), reinforcing the emerging principle that gut bacteria exert anti-IBD effects not only by direct immune modulation but by reconfiguring host cell metabolism. Taken together, these studies suggest that the therapeutic potential of microbiome interventions in IBD is mechanistically diverse and increasingly tractable, with the ER/GLS2 axis representing a novel and potentially druggable node in this network.

• Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice
  Both use the DSS-induced colitis mouse model to test microbiota-targeting interventions, but [id=118] acts through dietary polysaccharide-driven community remodeling rather than a single defined commensal, allowing direct comparison of top-down vs. bottom-up microbiome strategies.
• Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review
  Provides a mechanistic and clinical framework for how probiotics and commensal bacteria protect intestinal and systemic health through epithelial and immune pathways — readers can benchmark the ER/GLS2 mechanism against the broader landscape of characterized probiotic actions.
• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Demonstrates that IBD amelioration can be achieved through metabolite-driven reprogramming of immune cells (macrophages via lithocholic acid) rather than epithelial metabolism, offering a mechanistically distinct but therapeutically parallel comparison to the ER/GLS2/NF-κB epithelial axis.
• Emapunil attenuates ulcerative colitis by suppressing Z-DNA binding protein 1 driven pyroptosis and pro-inflammatory polarization in macrophages
  Addresses ulcerative colitis treatment through a completely different molecular target — ZBP1-driven pyroptosis suppression — allowing readers to contrast inflammatory pathway selectivity and ask whether GLS2 upregulation and pyroptosis inhibition are independent or interacting protective mechanisms.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Examines how a well-characterized probiotic yeast (Saccharomyces boulardii) restores intestinal barrier function, providing a directly comparable barrier-integrity endpoint to evaluate against ER's tight-junction restoration, with the added contrast of fungal vs. bacterial therapeutic organisms.